Allakos Inc. (NASDAQ: ALLK)
$0.86
+0.0028 ( +0.33% ) 510.1K
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Market Data
Open
$0.86
Previous close
$0.86
Volume
510.1K
Market cap
$76.41M
Day range
$0.85 - $0.91
52 week range
$0.72 - $5.64
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Feb 12, 2024 |
8-k | 8K-related | 12 | Feb 02, 2024 |
3 | Insider transactions | 1 | Jan 26, 2024 |
8-k | 8K-related | 46 | Jan 17, 2024 |
8-k | 8K-related | 12 | Jan 16, 2024 |
4 | Insider transactions | 1 | Dec 05, 2023 |
4 | Insider transactions | 1 | Dec 05, 2023 |
4 | Insider transactions | 1 | Dec 05, 2023 |
4 | Insider transactions | 1 | Dec 05, 2023 |
10-q | Quarterly Reports | 64 | Nov 13, 2023 |